Research Analysts Issue Forecasts for Altimmune Q3 Earnings

Key Points

• William Blair analysts raised their Q3 2025 earnings estimate for Altimmune to ($0.32) per share, improving from a previous estimate of ($0.34).
• The company reported quarterly earnings of ($0.27) EPS, exceeding the consensus estimate by $0.05, despite a negative net margin and return on equity.
• Altimmune's stock has a current market capitalization of $323.47 million and has experienced a 52-week price range between $2.90 and $11.16.

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Equities research analysts at William Blair upped their Q3 2025 EPS estimates for shares of Altimmune in a research report issued on Tuesday, August 12th. William Blair analyst A. Hsieh now anticipates that the company will post earnings of ($0.32) per share for the quarter, up from their prior estimate of ($0.34). William Blair has a "Market Perform" rating on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share. William Blair also issued estimates for Altimmune's Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.19) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.43) EPS and FY2027 earnings at ($1.49) EPS.

Other analysts also recently issued reports about the stock. JMP Securities reduced their price target on shares of Altimmune from $25.00 to $15.00 and set a "market outperform" rating on the stock in a report on Thursday, July 10th. B. Riley reduced their target price on shares of Altimmune from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. Wall Street Zen upgraded shares of Altimmune from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. UBS Group reduced their target price on shares of Altimmune from $26.00 to $24.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. Finally, HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of Altimmune in a report on Wednesday, August 13th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $17.40.

Altimmune Price Performance

NASDAQ ALT traded up $0.01 on Friday, reaching $3.63. The company had a trading volume of 2,218,988 shares, compared to its average volume of 3,770,638. The company has a quick ratio of 20.44, a current ratio of 20.44 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $320.37 million, a PE ratio of -3.08 and a beta of -0.01. The firm's 50 day moving average price is $4.64 and its 200 day moving average price is $5.23. Altimmune has a 12 month low of $2.90 and a 12 month high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.05. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%.

Hedge Funds Weigh In On Altimmune

Large investors have recently bought and sold shares of the business. Ameriprise Financial Inc. lifted its position in shares of Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after purchasing an additional 1,378,854 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Altimmune by 13.4% in the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company's stock worth $7,489,000 after purchasing an additional 228,995 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Altimmune by 9.5% in the fourth quarter. Bellevue Group AG now owns 945,446 shares of the company's stock worth $6,817,000 after purchasing an additional 81,786 shares during the last quarter. Federated Hermes Inc. boosted its position in Altimmune by 387.7% in the 2nd quarter. Federated Hermes Inc. now owns 915,458 shares of the company's stock valued at $3,543,000 after buying an additional 727,731 shares during the period. Finally, Bank of America Corp DE boosted its position in Altimmune by 155.2% in the 2nd quarter. Bank of America Corp DE now owns 716,019 shares of the company's stock valued at $2,771,000 after buying an additional 435,467 shares during the period. Hedge funds and other institutional investors own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.